

Biagio Ricciuti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2706625/publications.pdf>

Version: 2024-02-01

152
papers

4,967
citations

136950

32
h-index

133252

59
g-index

157
all docs

157
docs citations

157
times ranked

6694
citing authors

#	ARTICLE	IF	CITATIONS
1	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
2	Association between immune-related adverse event timing and treatment outcomes. <i>Oncolmmunology</i> , 2022, 11, 2017162.	4.6	33
3	Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1640-1650.	7.0	19
4	Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities. <i>Tumori</i> , 2022, , 030089162110694.	1.1	0
5	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
6	Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥50%) Tumor Proportion Score (TPS) /Overl	1.8	0
7	Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9021-9021.	1.6	1
8	Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after surgical resection.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8514-8514.	1.6	1
9	Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥50%) non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9054-9054.	1.6	0
10	Activating MET kinase domain mutations define a novel molecular subtype of non-small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9124-9124.	1.6	1
11	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
12	Three-year outcomes and correlative analyses in patients with non-small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥90% treated with first-line pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9043-9043.	1.6	3
13	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9066-9066.	1.6	1
14	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. <i>Cancer</i> , 2022, 128, 3067-3079.	4.1	15
15	Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9056-9056.	1.6	1
16	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9065-9065.	1.6	4
17	Impact of STK11 copy loss on clinical outcomes to PD-(L)1 blockade in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9059-9059.	1.6	0
18	Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21178-e21178.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Antibody-drug conjugates for lung cancer in the era of personalized oncology. <i>Seminars in Cancer Biology</i> , 2021, 69, 268-278.	9.6	17
20	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	3.0	4
21	Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. <i>Scientific Reports</i> , 2021, 11, 6637.	3.3	12
22	Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 2566-2573.	0.9	69
23	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
24	Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1857-1872.	2.8	41
25	DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9113-9113.	1.6	2
26	Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9088-9088.	1.6	4
27	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9121-9121.	1.6	2
28	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9119-9119.	1.6	0
29	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9018-9018.	1.6	4
30	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. <i>JCO Precision Oncology</i> , 2021, 5, 726-732.	3.0	10
31	Changes in PD-L1 tumor proportion score are associated with <i>CD274</i> gene (encoding PD-L1) copy number variation in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9029-9029.	1.6	0
32	Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1761-1769.	6.3	27
33	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. <i>Genes</i> , 2021, 12, 992.	2.4	5
34	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	1.1	49
35	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 1391-1399.	1.2	32
36	Response to Hopkins, Kichenadasse, Logan, et al. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	0

#	ARTICLE	IF	CITATIONS
37	Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. <i>Journal of Thoracic Oncology</i> , 2021, , .	1.1	21
38	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
39	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of cliniciansâ€™ attitudes. <i>Clinical and Translational Oncology</i> , 2020, 22, 844-851.	2.4	21
40	ROS1-rearranged Nonâ€™small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020, 21, 15-20.	2.6	58
41	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 708-716.	2.4	6
42	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64.	2.0	33
43	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	1.6	135
44	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression â‰¥ 50%: a multicenter study with external validation. , 2020, 8, e001403.		57
45	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. , 2020, 8, e000678.		78
46	Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Radiology</i> , 2020, 132, 109275.	2.6	13
47	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â‰¥50%) nonâ€™small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
48	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Nonâ€™Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	7.1	241
49	What Is the Standard First-Line Treatment for Advanced Nonâ€™Small Cell Lung Cancer?. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 485-495.	2.0	5
50	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Nonâ€™Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	7.0	95
51	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥50%. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
52	Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, 807-814.	1.2	65
53	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression â‰¥ 50% and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
54	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. <i>Future Oncology</i> , 2020, 16, 1751-1766.	2.4	20

#	ARTICLE	IF	CITATIONS
55	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1177-1187.	4.2	66
56	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	2.8	85
57	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2615-2625.	7.0	129
58	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression $\geq 50\%$. <i>Annals of Oncology</i> , 2020, 31, 404-411.	1.2	79
59	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. <i>Lung Cancer</i> , 2020, 145, 181-185.	2.0	36
60	Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. <i>Clinical Lung Cancer</i> , 2020, 21, e478-e487.	2.6	2
61	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
62	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
63	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	1.1	10
64	Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3518-3518.	1.6	4
65	Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9042-9042.	1.6	1
66	Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9549-9549.	1.6	7
67	Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9577-9577.	1.6	2
68	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15113-e15113.	1.6	7
69	Outcomes to first-line pembrolizumab in patients with PD-L1-high ($\geq 50\%$) non-small-cell lung cancer and a poor performance status.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9568-9568.	1.6	0
70	Influence of antibiotic therapy (ATB) on oncological outcomes of metastatic non-small cell lung cancer (mNSCLC) patients treated with chemo-immunotherapy (CIT).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3080-3080.	1.6	0
71	Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). <i>Translational Lung Cancer Research</i> , 2020, 9, 2428-2439.	2.8	21
72	Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14 Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100072.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Reply to Cortellini A. JTO Clinical and Research Reports, 2020, 1, 100095.	1.1	1
74	Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Annals of Oncology, 2019, 30, 1653-1659.	1.2	220
75	Reply to J. Delyon et al. Journal of Clinical Oncology, 2019, 37, 3564-3565.	1.6	0
76	Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. Journal of Thoracic Disease, 2019, 11, S1831-S1834.	1.4	5
77	Emerging Biomarkers in the Era of Personalized Cancer Medicine. Disease Markers, 2019, 2019, 1-2.	1.3	2
78	<p>Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence</p>. OncoTargets and Therapy, 2019, Volume 12, 3171-3179.	2.0	38
79	Immune Checkpoint Inhibitor Outcomes for Patients With Non"Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology, 2019, 37, 1927-1934.	1.6	220
80	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology, 2019, 37, 2738-2745.	1.6	138
81	Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. Journal of Thoracic Disease, 2019, 11, S249-S252.	1.4	2
82	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	3.7	131
83	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
84	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
85	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
86	Safety and Efficacy of Nivolumab in Patients With Advanced Non"small-cell Lung Cancer Treated Beyond Progression. Clinical Lung Cancer, 2019, 20, 178-185.e2.	2.6	35
87	Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor na˜ve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option. Translational Lung Cancer Research, 2019, 8, S378-S382.	2.8	1
88	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non"Small-Cell Lung Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	58
89	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Translational Lung Cancer Research, 2019, 8, 1163-1173.	2.8	34
90	MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. Journal of Thoracic Oncology, 2019, 14, S294-S295.	1.1	3

#	ARTICLE	IF	CITATIONS
91	P1.04-04 DNA Damage Response Gene Alterations Are Associated with High Tumor Mutational Burden and Clinical Benefit from PD-1 Axis Inhibition in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, S439-S440.	1.1	0
92	OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, S213-S214.	1.1	2
93	P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, S384-S385.	1.1	0
94	MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S285.	1.1	4
95	775 Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, S450-S451.	0.4	1
96	P2.04-32 Comparison of Clinicopathological and Genomic Characteristics Between NSCLCs with a PD-L1 Tumor Proportion Score of $\geq 90\%$ vs $< 1\%$. <i>Journal of Thoracic Oncology</i> , 2019, 14, S720-S721.	1.1	2
97	High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 12-24.	7.1	49
98	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. , 2019, 196, 105-116.		88
99	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 479-485.	2.5	253
100	Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. <i>Seminars in Cancer Biology</i> , 2019, 56, 87-99.	9.6	33
101	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2577-2577.	1.6	2
102	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9077-9077.	1.6	2
103	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9082-9082.	1.6	4
104	Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score $\geq 90\%$.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9111-9111.	1.6	4
105	Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.. <i>Journal of Clinical Oncology</i> , 2019, 37, 118-118.	1.6	1
106	A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 135-143.	2.8	12
107	Immune gene expression and bayesian network analysis in advanced non small cell lung cancer (NSCLC) patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20693-e20693.	1.6	1
108	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. <i>Medical Oncology</i> , 2018, 35, 72.	2.5	29

#	ARTICLE	IF	CITATIONS
109	Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. <i>Lung Cancer</i> , 2018, 120, 70-74.	2.0	5
110	Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e9-e12.	1.1	8
111	Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy. , 2018, 181, 156-168.		102
112	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. <i>Medical Oncology</i> , 2018, 35, 4.	2.5	17
113	Fatal acute disseminated intravascular coagulation as presentation of advanced ALK -positive non-small cell lung cancer: Does oncogene addiction matter?. <i>Thrombosis Research</i> , 2018, 163, 51-53.	1.7	12
114	First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, S127-S130.	2.8	2
115	Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme. <i>Annals of Oncology</i> , 2018, 29, x18-x19.	1.2	1
116	MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Thoracic Oncology</i> , 2018, 13, S390-S391.	1.1	4
117	P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, S464-S465.	1.1	0
118	P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience. <i>Journal of Thoracic Oncology</i> , 2018, 13, S611.	1.1	0
119	Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880865.	2.6	22
120	KRAS mutation and DNA repair and synthesis genes in non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 689-696.	1.0	7
121	Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e220-e222.	1.1	5
122	Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. <i>Journal of Thoracic Oncology</i> , 2018, 13, e145-e147.	1.1	15
123	Osimertinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 257-276.	1.8	24
124	High density lipoprotein cholesterol and cancer: Marker or causative?. <i>Progress in Lipid Research</i> , 2018, 71, 54-69.	11.6	79
125	Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9084-9084.	1.6	2
126	Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 177-177.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.. Journal of Clinical Oncology, 2018, 36, e15158-e15158.	1.6	0
128	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Medical Oncology, 2017, 34, 105.	2.5	47
129	Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e51-e55.	1.1	3
130	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 101-109.	2.4	8
131	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404.	3.2	30
132	Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clinic Proceedings, 2017, 92, 1304-1311.	3.0	24
133	Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. Journal of Radiation Oncology, 2017, 6, 11-19.	0.7	1
134	Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels. Annals of Oncology, 2017, 28, vi58-vi59.	1.2	0
135	Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. Journal of Breast Cancer, 2016, 19, 324.	1.9	14
136	Malignant Giant Solitary Fibrous Tumor of the Pleura Metastatic to the Thyroid Gland. Tumori, 2016, 102, S16-S21.	1.1	6
137	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 2016, 95, 82-87.	2.0	19
138	Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Clinical Drug Investigation, 2016, 36, 683-686.	2.2	27
139	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. ESMO Open, 2016, 1, e000022.	4.5	15
140	Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. Journal of Neuro-Oncology, 2016, 129, 355-361.	2.9	25
141	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Management, 2016, 5, 79-90.	1.5	1
142	Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Medical Oncology, 2016, 33, 18.	2.5	129
143	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine, 2016, 10, 53-68.	2.5	56
144	Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis. Annals of Oncology, 2015, 26, vi78.	1.2	3

#	ARTICLE	IF	CITATIONS
145	Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. <i>Ecancelmedicalsience</i> , 2015, 9, 559.	1.1	11
146	miRNAs and resistance to EGFR TKIs in EGFR-mutant non-small cell lung cancer: beyond traditional mechanisms of resistance. <i>Ecancelmedicalsience</i> , 2015, 9, 569.	1.1	12
147	Melanosis coli or ischaemic colitis? That is the question. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212404.	0.5	5
148	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 211-219.	2.0	50
149	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2601-2613.	1.8	22
150	Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking. <i>BMJ Case Reports</i> , 2015, 2015, .	0.5	1
151	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. <i>Clinical Lung Cancer</i> , 2014, 15, 86-92.	2.6	40
152	Non-coding RNAs in lung cancer. <i>Oncoscience</i> , 2014, 1, 674-705.	2.2	33